NEUROONE MEDICAL TECHNOLOGIES Corp — Form 8-K
Filed August 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
NeuroOne completed three large-animal procedures at University of Minnesota using its next-generation StereoCED platform, demonstrating combined drug delivery and electrophysiological recording in two of three cases. The company expects to recognize related StereoCED revenue in Q4 2026 from this preclinical research program and plans to launch the platform for human investigational clinical studies by end of Q4 2026. No dollar amounts, revenue figures, or specific commercial terms are disclosed.
Why this rating
Meaningful preclinical milestone de-risks StereoCED commercialization for $25.5M company; however, no revenue quantified, regulatory path uncertain, and human trials not yet initiated. Early-stage asset validation.
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.